Entrada Therapeutics (NASDAQ:TRDA) Upgraded by Wall Street Zen to "Hold" Rating

Wall Street Zen upgraded shares of Entrada Therapeutics (NASDAQ:TRDA - Free Report) from a sell rating to a hold rating in a research report sent to investors on Friday morning.

Separately, HC Wainwright reaffirmed a "buy" rating and issued a $20.00 price objective on shares of Entrada Therapeutics in a research note on Tuesday, May 20th. One equities research analyst has rated the stock with a hold rating, three have given a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat.com, Entrada Therapeutics has a consensus rating of "Buy" and an average price target of $25.67.

Entrada Therapeutics Stock Down 2.7%

Shares of TRDA stock traded down $0.19 on Friday, reaching $6.72. The company had a trading volume of 160,972 shares, compared to its average volume of 133,630. The business's 50-day moving average is $8.01 and its 200 day moving average is $10.88. Entrada Therapeutics has a one year low of $6.71 and a one year high of $21.79. The stock has a market capitalization of $255.02 million, a PE ratio of 8.30 and a beta of -0.06.

Entrada Therapeutics (NASDAQ:TRDA - Get Free Report) last released its quarterly earnings data on Thursday, May 8th. The company reported ($0.42) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.78) by $0.36. Entrada Therapeutics had a return on equity of 5.84% and a net margin of 14.39%. The company had revenue of $8.75 million during the quarter, compared to the consensus estimate of $10.98 million. On average, sell-side analysts forecast that Entrada Therapeutics will post 1.12 earnings per share for the current fiscal year.

Institutional Trading of Entrada Therapeutics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in TRDA. Charles Schwab Investment Management Inc. increased its position in Entrada Therapeutics by 6.0% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 197,127 shares of the company's stock valued at $3,408,000 after purchasing an additional 11,143 shares during the period. AlphaQuest LLC acquired a new stake in shares of Entrada Therapeutics during the 4th quarter worth approximately $70,000. American Century Companies Inc. grew its position in shares of Entrada Therapeutics by 17.7% during the 4th quarter. American Century Companies Inc. now owns 59,710 shares of the company's stock worth $1,032,000 after buying an additional 8,985 shares during the period. KLP Kapitalforvaltning AS acquired a new stake in shares of Entrada Therapeutics during the 4th quarter worth approximately $36,000. Finally, LPL Financial LLC grew its position in shares of Entrada Therapeutics by 12.9% during the 4th quarter. LPL Financial LLC now owns 55,154 shares of the company's stock worth $954,000 after buying an additional 6,310 shares during the period. Institutional investors and hedge funds own 86.39% of the company's stock.

Entrada Therapeutics Company Profile

Entrada Therapeutics, Inc, a clinical-stage biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its EEV platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. Its therapeutic candidates, which include ENTR-601-44, which is in Phase I clinical trial for the treatment of Duchenne muscular dystrophy; and ENTR-701, which is in Phase 1/2 clinical trial for the treatment of myotonic dystrophy type 1.